Mixed Race Studies

CUNY DSI Monograph Documents Dominican Heritage of First Settler

The City University of New York
City College
2012-10-04

Juan Rodríguez, native of Santo Domingo, comes to New York in 1613 and stays when his ship sails to Holland

The first non-native to live in what is now New York City was a black or mixed race Dominican, a new monograph produced by researchers at the CUNY Dominican Studies Institute (CUNY DSI) documents. Juan Rodríguez, who was born on the colony of La Española, now the Dominican Republic, came to the Big Apple in 1613 aboard a Dutch trading vessel en route from the Caribbean. He decided to stay and live among the natives when the ship returned to Holland.
 
“This is the kind of research that produces new academic knowledge and engages in a conversation with a scholarly community who studies New York City’s early history,” said Dr. Ramona Hernández, director of CUNY DSI. “This research also serves people from a practical point of view: A very early predecessor of the large Dominican population that thrives in New York City today, Juan Rodriguez’s story belongs to the history of all New Yorkers.
 
“As residents of a port city with a uniquely multiethnic population since its very beginnings next to the mighty Hudson River, New York has always been a community of interactions and intermingling amongst races and ethnicities.”
 
The monograph was commissioned by the American Chamber of Commerce of the Dominican Republic, which will receive the first copy at a luncheon meeting at City College Thursday, October 4. The following day, a two-hour colloquium with experts in translations and transcription will examine the challenges, excitement and insights of translating the documentation for the Juan Rodríguez story.
 
Earlier this week, New York City Mayor Michael Bloomberg named a stretch of Broadway between W. 159th Street and W. 218th Street for Mr. Rodríguez. The section of the famed roadway runs through Washington Heights, home of one of the largest concentrations of Dominicans living outside their homeland.
 
According to archival records reviewed by DSI researchers, Mr. Rodríguez, a black or mulatto free sailor born on La Española, arrived in an estuary of the Hudson River in the spring of 1613, aboard the “Jonge Tobias,” a Dutch ship captained by Thijs Mossel. After two months presumably spent trading with Native Americans, Captain Mossel decided to return to Holland, but Mr. Rodríguez refused to make the journey and was allowed to stay on shore…

Read the entire article here.

Race-Based Medicine: Déjà Vu All Over Again?

Biopolitical Times: The weblog of the Center for Genetics and Society
2012-09-18

Osagie K. Obasogie, Associate Professor of Law
University of California, San Francisco
Also: Senior Fellow
Center for Genetics and Society

Race-based medicine has been one of the more contentious issues in pharmaceutical research and development over the past few years. Some argue that drugs specifically labeled to treat particular racial groups offer an invaluable way to fight racial disparities in health by targeting at-risk populations. Others claim that race-based medicine inappropriately treats race as a biological cause of racial disparities when broader social and environmental factors may offer better explanations.

Much of this debate involves the FDA’s 2005 approval of BiDil, which became the first drug to be labeled for a specific racial group – African Americans with heart failure. The heat generated from this debate has largely faded due to BiDIl’s market failure.  But, it seems like a new drug may reignite a few flames.

Tradjenta was developed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly to treat Type 2 diabetes. But results from a Phase III clinical trial recently showed that Tradjenta was particularly beneficial for controlling African Americans’ blood sugar levels…

…Is another BiDil on the horizon? It’s important to acknowledge that Tradjenta had already received FDA approval to treat type 2 diabetes in the general population prior to the announcement of these race-specific results. This is different from BiDil, where investigators sought a race-specific indication from the FDA because they could not otherwise win regulatory approval as a race-neutral drug. Despite these differences, treating racial disparities in diabetes as a naturally observed group difference that can be at least partially resolved with a pill shares some similarities with the BiDil saga. In both cases, there is a tendency to naturalize racial disparities as a function of group difference rather than having a deeper engagement with the social determinants of health.

This leads to an important question: if Tradjenta already received approval for use in the general population, why would it not be effective in African Americans? Put differently, why go through the time and expense of conducting a clinical trial to demonstrate efficacy in a particular racial group when the drug has already been approved for everyone regardless of race?

It’s unclear how these recent clinical trial results might be used. Perhaps this is another example of using a clinical trial as a marketing device in the hopes of capturing a larger share of the market…

Read the entire article here.

Deep Roots and Tangled Branches

The Chronicle of Higher Education
2006-02-03

Troy Duster, Chancellor’s Professor of Sociology
University of California, Berkeley
Also Professor of Sociology and Director of the Institute for the History of the Production of Knowledge
New York University

People who know their biological parents and grandparents typically take the information for granted. Some have a difficult time empathizing with the passionate genealogical quests of adoptees and, increasingly, products of anonymous sperm banks and other new technologies where one or both genetic contributors are unknown. In recent years, new legislation has enabled people to search for information about genetic progenitors – even in cases where there had been a signed agreement of nondisclosure. The laserlike focus of that search can be as relentless as Ahab’s hunt for the white whale.

Mystery of lineage is the stuff of great literature. Mark Twain made use of it for biting social commentary in his Pudd’nhead Wilson, a story about the mix-up of babies born to a slave and a free person. Sophocles, Shakespeare, Molière, and Dickens built grand tragedy and enduring comedy on the theme. In England in 2002, a white Englishwoman gave birth to mixed-race twins after a mix-up at an in vitro fertilization clinic. Imagine what Shakespeare would have done with that!

If one person’s passions can be so riled by such a puzzle, imagine the emotions involved when the uncertainty applies to a whole group – say, of 12 million people. The middle passage did just that to Americans of recent African descent. Names were obliterated from record books, and slaves were typically anointed with a new single first name. Sometimes no names were recorded, just the slaves’ numbers, ages, and genders. Some African-Americans have deliberately and actively participated in the erasure, showing no desire to pursue a genealogical trail. For others, fragments of oral history generate a fierce longing to do the detective work.

That is the case among the prominent subjects featured in “African American Lives,” a two-night, four-part PBS series scheduled for February 1 and 8. The host and executive co-producer is Henry Louis Gates Jr., chairman of the department of African and African-American studies at Harvard. Gates has assembled eight notably successful African-Americans, among them the media entrepreneur Oprah Winfrey, the legendary music producer Quincy Jones, and the film star Whoopi Goldberg. Each participant, along with Gates, is the subject of some serious professional family-tree tracing. There are surprises for each of them, and the series has undeniable human-interest appeal…

Read the entire article here.

Racial Labels Have Limited Use In Personalizing Medicine

Shots: NPR’s Health Blog
2011-05-09

Eliza Barclay

For all the fanfare around personalized medicine, the idea has been fairly slow to take off.

Boosters have said if doctors had a patient’s DNA information it would be revolutionary: They could look for genetic risk of certain diseases or mutations that determine whether certain drugs are likely to work or not.

The cost of DNA sequencing keeps falling, yet genetic sequencing for medical use isn’t commonplace. In the meantime, doctors can, in theory, consider a patient’s race in anticipating health conditions that could pose a higher risk.
 
But a study published recently in PLoS One suggests that using race as a stand in for truly personalized genetic information may not work, especially in the most diverse cities (like New York and Los Angeles) that attract immigrants from around the world.

There’s a lot of genetic variability among races. And the genetic risk profiles for many people with mixed ancestry don’t fit neatly into any category…

Read the entire article here.

White persons and Malayans are forbidden to intermarry and both are forbidden to marry Negroes or persons of Negro descent to the third generation. The statutory mode of expression to cover persons of mixed white and Negro blood is an awkward one and makes doubtful just what proportion of Negro blood will disqualify one from marrying a pure white person or Malayan. It is suggested that if the person in question has some non-Negro blood and that if all of his parents and grand-parents also had some, he is eligible for purposes of the statute, even though he is predominantly Negro.

John S. Strahorn Jr., “Void and Voidable Marriages in Maryland and Their Annulment,” Maryland Law Review, Volume 2, Issue 3 (1938): 231.

Slooooooow Sales for BiDil^®

Biopolitical Times: The weblog of the Center for Genetics and Society
2006-10-18

Osagie K. Obasogie, Associate Professor of Law
University of California, San Francisco
Also: Senior Fellow
Center for Genetics and Society

Today’s Wall Street Journal reports that sales for BiDil^®—the first drug to receive FDAapproval to treat a specific race—are unexpectedly slow. Marketed as treating heart failure in African-Americans, BiDil^® was expected to generate $130 million in sales this year; thus far, only a little over $5 million has come in. Estimates show that only 1% of the 750,000 Blacks suffering from heart failure are using it.

There’s no shortage of explanations for why Black people are about as unlikely to take BiDil^® as they are to name a newborn child Katrina…

…But, perhaps there’s another explanation that the Wall Street wing tips are missing: a sense of history.

During a conference I attended earlier this year on BiDil^® and race specific medicines, an older Black woman in the audience stood up and said “If I were sick and somebody told me that they had a drug just for Black people to help me, I’d say to them: give me what the white people are taking.”…

Read the entire article here.

The Biopolitics of Mixing: Thai Multiracialities and Haunted Ascendancies

Ashgate Publishing
October 2012
198 pages
234 x 156 mm
Hardback ISBN: 978-0-7546-7680-5
ebook ISBN 978-1-4094-2502-1

Jinthana Haritaworn, Assistant Professor in Gender, Race and Environment at the Faculty of Environmental Studies
York University, Canada

Debates over who belongs in Europe and who doesn’t increasingly speak the language of mixing, but how are the figures commonly described as ‘mixed’ actually embodied? The Biopolitics of Mixing invites us to reckon with the spectres of pathologization past and present, placing the celebration of mixing beside moral panics over terrorism and trafficking and a post-race multiculturalism that elevates some as privileged members of the neoliberal community, whilst ghosting others from it. Drawing on a broad archive including rich qualitative interviews conducted in Britain and Germany, media and policy debates, popular culture, race-based research and queer-of-colour theories, this book imagines into being communities in which people and places normally kept separate can coexist in the same reality.

As such, it will appeal to scholars across a range of sociological and cultural studies, including critical race, ethnic and migration studies, transnational gender and queer studies, German and European studies, Thai and Southeast Asian studies, and studies of affect, performativity, biopolitics and necropolitics. It should be read by all those interested in thinking critically on the intersections of race, class, gender, sexuality and disability.

Contents

• Introduction: haunted origins
• Where are you from?
• From monster to fashion model: regenerating racialized bodies
• Is it better to be mixed race?
• Hybrid nations, mixed feelings: from marginal man to Obama
• Exceptional cities, exceptional citizens: metronormativity and mimeticism
• Reckoning with prostitutes: performing Thai femininity
• Conclusion: where do we want to go?
• Bibliography
• Index